for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA

SASY.PA

現在値

87.64EUR

変化

--(--)

本日のレンジ

--

 - 

--

52週レンジ

74.92

 - 

95.82

∙ 約20分前の相場を表示しています。

適時開示

Genomic Vision Completes First Milestone In Sanofi Partnership

May 14 (Reuters) - GENOMIC VISION SA <GVI.PA>::ANNOUNCED ON THURSDAY PURSUIT OF ITS PARTNERSHIP WITH SANOFI AND COMPLETION OF ITS FIRST MILESTONE.COMPLETED WORK PACKAGE ONE OF THREE-PART RESEARCH AGREEMENT FOR GENETIC CHARACTERIZATION OF SANOFI CELL BANKS.IN PARALLEL, CONTINUES WORKING WITH NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY CONSORTIUM TO DEVELOP QUALITY CONTROL TOOLS TO BE USED IN GENOME EDITING BASED THERAPIES.

Innate Pharma Q1 Revenues Down At EUR 4.5 Mln

May 11 (Reuters) - INNATE PHARMA SA <IPH.PA>::CASH POSITION OF EUR 181.7 MILLION¹ AS OF MARCH 31, 2021.LACUTAMAB TELLOMAK TRIAL PROGRESSES AS KIR3DL2-EXPRESSING MYCOSIS FUNGOIDES COHORT ADVANCES TO STAGE 2 AFTER POSITIVE EARLY SIGNAL.COMPANY'S FIRST NK CELL ENGAGER SELECTED BY SANOFI AS DRUG CANDIDATE FOR DEVELOPMENT.REVENUES FOR FIRST THREE MONTHS OF 2021 AMOUNTED TO EUR 4.5 MILLION (EUR 19.3 MILLION FOR SAME PERIOD IN 2020).

Sanofi: 97.39% Of Kiadis Shares In Total Committed Under Offer

April 29 (Reuters) - Sanofi SA <SASY.PA>::FINAL RESULTS OF THE OFFER FOR KIADIS: 97.39% OF KIADIS SHARES IN TOTAL COMMITTED UNDER THE OFFER.WILL INITIATE THE STATUTORY BUY-OUT IN AN EXPEDITIOUS MANNER IN ORDER TO OBTAIN 100% OF THE SHARES OF KIADIS PHARMA.

Sanofi Q1 Net Income Down At EUR 1.58 Bln

April 28 (Reuters) - Sanofi SA <SASY.PA>::Q1 NET SALES EUR 8.59 BILLION VERSUS. EUR 8.97 BILLION YEAR AGO.Q1 OPERATING INCOME EUR 2.06 BILLION VERSUS. EUR 2.05 BILLION YEAR AGO.Q1 NET INCOME EUR 1.58 BILLION VERSUS. EUR 1.70 BILLION YEAR AGO.END-Q1 FREE CASH FLOW EUR 1.93 BILLION VERSUS. EUR 1.56 BILLION YEAR AGO.OUTLOOK 2021: APPLYING AVERAGE APRIL 2021 EXCHANGE RATES, CURRENCY IMPACT ON 2021 BUSINESS EPS IS ESTIMATED TO BE BETWEEN 4% TO 5%.FULL YEAR 2021 BUSINESS EPS GUIDANCE AFFIRMED.Q1 BUSINESS EPS WAS EUR 1.61, UP 5.2% ON A REPORTED BASIS AND UP 15.0% AT CER.RESULTS FOR PHASE 2 STUDY FOR RECOMBINANT COVID-19 VACCINE CANDIDATE ARE EXPECTED NEXT MONTH.TRIALS RESULTS AND START OF GLOBAL PHASE 3 STUDY FOR ADJUVANTED RECOMBINANT PROTEIN COVID-19 VACCINE CANDIDATE (SP0253) ARE EXPECTED IN Q2 2021.INTERIM RESULTS FOR MRT5500 (SP0254), AN MRNA VACCINE CANDIDATE AGAINST SARS-COV-2, ARE EXPECTED IN Q3 2021.TO SUPPORT MANUFACTURING, SUPPLY OF BIONTECH’S MRNA COVID-19 VACCINE, CO DEVELOPED WITH PFIZER, PROVIDING FILL, FINISH FOR OVER 125 MILLION DOSES; INITIAL SUPPLIES TO ORIGINATE FROM SANOFI’S PRODUCTION FACILITIES IN FRANKFURT FROM SUMMER 2021.TO SUPPORT MANUFACTURING OF JANSSEN´S COVID-19 VACCINE AND THROUGH ITS VACCINE MANUFACTURING PLANT IN MARCY L’ETOILE, FORMULATE, FILL VIALS AT RATE OF ABOUT 12 MILLION DOSES PER MONTH.

Sanofi India March Qtr Profit Rises

April 27 (Reuters) - Sanofi India Ltd <SANO.NS>::SANOFI INDIA LTD - UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2021.SANOFI INDIA MARCH-QUARTER PROFIT 1.46 BILLION RUPEES VERSUS PROFIT 854 MILLION RUPEES YEAR AGO.SANOFI INDIA MARCH-QUARTER REVENUE FROM OPERATIONS 7.25 BILLION RUPEES VERSUS 7.85 BILLION RUPEES YEAR AGO.

Sanofi Says Positive Topline Results From Phase 3 Trial For Nirsevimab

April 26 (Reuters) - SANOFI SA <SASY.PA>::NIRSEVIMAB DEMONSTRATED PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS DISEASE IN HEALTHY INFANTS IN PHASE 3 TRIAL.NIRSEVIMAB IS BEING INVESTIGATED AS A FIRST-IN-CLASS SINGLE DOSE IMMUNIZATION TO PROVIDE PROTECTION FOR ALL INFANTS ENTERING THEIR FIRST RSV SEASON.NIRSEVIMAB MET ITS PHASE 3 PRIMARY ENDPOINT EARLIER THAN ANTICIPATED; REGULATORY SUBMISSIONS FOR ALL-INFANT INDICATION TO BEGIN IN 2022.RESPIRATORY SYNCYTIAL VIRUS (RSV) IS LEADING CAUSE OF HOSPITALIZATION IN ALL INFANTS.

Sanofi: New Dupixent Analyses

April 23 (Reuters) - SANOFI SA <SASY.PA>::NEW DUPIXENT® (DUPILUMAB) ANALYSES REINFORCE LONG-TERM SAFETY AND EFFICACY PROFILE IN PATIENTS WITH ATOPIC DERMATITIS AS YOUNG AS 6 YEARS.LATE-BREAKING PHASE 2 DATA FOR RILZABRUTINIB, AN INVESTIGATIONAL THERAPY FOR PEMPHIGUS VULGARIS, A RARE, DEBILITATING AUTOIMMUNE DISEASE, TO BE PRESENTED AT AAD.ADDITIONAL ANALYSES EVALUATED RESPONSE RATES ACROSS A BROAD POPULATION, AND IMPACT OF DUPIXENT ON DISEASE EXTENT AND SEVERITY, QUALITY OF LIFE (QOL), AND ITCH.

Sanofi: European Commission approval for second indication Of Sarclisa(®) (Isatuximab) for relapsed multiple myeloma

April 19 (Reuters) - Sanofi SA <SASY.PA>::REG-EUROPEAN COMMISSION APPROVES SECOND INDICATION OF SARCLISA® (ISATUXIMAB) FOR RELAPSED MULTIPLE MYELOMA.EUROPEAN COMMISSION APPROVES SECOND INDICATION OF SARCLISA(®) (ISATUXIMAB) FOR RELAPSED MULTIPLE MYELOMA.APPROVAL BASED ON PHASE 3 IKEMA STUDY.THIS MARKS SECOND EC APPROVAL OF SARCLISA IN COMBINATION WITH A STANDARD OF CARE REGIMEN IN LESS THAN 12 MONTHS..

Sanofi: previously announced offer for Kiadis is now unconditional

April 13 (Reuters) - Sanofi/Kiadis Pharma NV <KDS.AS>::REG-SANOFI DECLARES THE OFFER FOR KIADIS UNCONDITIONAL.REG-SANOFI DECLARES THE OFFER FOR KIADIS UNCONDITIONAL.SANOFI:- 95.03% OF KIADIS SHARES IN TOTAL COMMITTED UNDER OFFER.All Offer Conditions are now satisfied or waived..Settlement of the Offer will take place on 16 April 2021, at which date the Offer Price of EUR 5.45 per Tendered Share will be paid..

Sanofi to invest 400 mln euros in new vaccines production site in Singapore

April 12 (Reuters) - French drugmaker Sanofi SA <SASY.PA>::SANOFI TO INVEST IN A LEADING-EDGE PRODUCTION SITE IN SINGAPORE; CONTINUES TO STRENGTHEN ITS VACCINES MANUFACTURING CAPACITIES.SANOFI TO INVEST IN A LEADING-EDGE PRODUCTION SITE IN SINGAPORE; CONTINUES TO STRENGTHEN ITS VACCINES MANUFACTURING CAPACITIES.WILL INVEST EUR 400 MILLION OVER FIVE YEARS TO CREATE A UNIQUE VACCINE PRODUCTION SITE IN SINGAPORE.NEW SITE WILL PROVIDE SANOFI WITH ABILITY TO PRODUCE INNOVATIVE VACCINES ON A MASSIVE SCALE FOR ASIA, AND QUICKLY RESPOND TO FUTURE PANDEMIC RISKS..PROJECT IS EXPECTED TO CREATE UP TO 200 LOCAL JOBS AND ENHANCE SINGAPORE'S POSITION AS A REGIONAL INNOVATION HUB FOR HEALTHCARE INDUSTRY..Further company coverage: <SASY.PA>. (Reporting by Sudip Kar-Gupta). ((sudip.kargupta@thomsonreuters.com;)).

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up